Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Niroshini Naicker"'
Autor:
Robert Hawkins, Kate Fife, Michael Hurst, Meng Wang, Niroshini Naicker, Sarah Nolasco, Tim Eisen, Athena Matakidou, Jason Gordon
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world evidence is limited. Thus, this study aimed to
Externí odkaz:
https://doaj.org/article/d065a4dd2bdb4aab9256cfc32e1e1765
Autor:
Meng Wang, Robert E. Hawkins, Jason Gordon, Niroshini Naicker, Tim Eisen, Michael Hurst, Kate Fife, Sarah Nolasco, Athena Matakidou
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Funder: Bristol Myers Squibb Pharmaceuticals Ltd.
Background: Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world
Background: Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f8dbf28af7314b66371bcceeed7a35
http://europepmc.org/articles/PMC7368711
http://europepmc.org/articles/PMC7368711
Autor:
Hawkins, Robert, Fife, Kate, Hurst, Michael, Wang, Meng, Niroshini Naicker, Nolasco, Sarah, Eisen, Tim, Matakidou, Athena, Gordon, Jason
Additional file 1: Supplementary Table 1. Time-to-events by LOT. Supplementary Table 2. Adverse events by LOT. Supplementary Figure 1. Treatment pathways for patients receiving systemic therapies. Supplementary Figure 2. Overall survival from 2LOT st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ea7f8c13972abf0be18a39e96157faf
